Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted
You may also be interested in...
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.
A Sangstat co-promotion agreement with Abbott for its SangCya oral cyclosporine products will provide the company with an experienced partner in the managed care and hospital marketing areas.
FDA's elimination of "microemulsion" dosage forms is unlawful, Novartis contended in a Feb. 11 lawsuit challenging FDA's approval of SangStat's generic version of Neoral (cyclosporine).